Gilead Sciences (GILD) Accumulated Expenses (2009 - 2022)

Gilead Sciences has reported Accumulated Expenses for 14 years, with the latest figure at $3.7 billion in Q3 2022.

• For the quarter ending Q3 2022, Accumulated Expenses fell 2.83% year-over-year to $3.7 billion; the trailing twelve-month figure through Sep 2022 stood at $3.7 billion (down 2.83% YoY), and the FY2021 full-year result was $3.2 billion, down 25.18% from the prior year.
• Accumulated Expenses for Q3 2022 stood at $3.7 billion, down from $4.1 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $5.0 billion in Q1 2018, with the low at $2.3 billion in Q1 2019.
• Historically, Accumulated Expenses has averaged $3.7 billion across 5 years, with a median of $3.7 billion in 2019.
• Annual changes were most pronounced in 2019 — Accumulated Expenses sank 53.49% — and 2020, when it soared 47.23%.
• Gilead Sciences' Accumulated Expenses stood at $3.9 billion in 2018, then retreated by 11.58% to $3.5 billion in 2019, then climbed by 24.85% to $4.3 billion in 2020, then decreased by 25.18% to $3.2 billion in 2021, then advanced by 13.26% to $3.7 billion in 2022.
• The last three Accumulated Expenses figures came in at $3.7 billion (Q3 2022), $4.1 billion (Q2 2022), and $3.4 billion (Q1 2022), per Business Quant data.